A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone

• Status: Active, not recruiting
• Trial end date: 2022-03-31

Summary

The purpose of the study is to understand if there is benefit in continued treatment with a medicine called enzalutamide, when starting treatment with docetaxel and prednisolone (a standard chemotherapy for prostate cancer), after the prostate cancer has gotten worse when treated with enzalutamide alone.

• Phase: Phase 3

Details

• Lead Sponsor: Astellas Pharma Europe Ltd.
• Collaborators: Medivation LLC, a wholly owned subsidiary of Pfizer Inc.; Medivation, Inc.
• Treatments: Docetaxel; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate